skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: British Journal Of Dermatology remover assunto: Male remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Griffiths, C.E.M. ; Thaçi, D. ; Gerdes, S. ; Arenberger, P. ; Pulka, G. ; Kingo, K. ; Weglowska, J. ; Hattebuhr, N. ; Poetzl, J. ; Woehling, H. ; Wuerth, G. ; Afonso, M.

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
2
Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study
Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study

Giunta, A. ; Manfreda, V. ; Esposito, M. ; Del Duca, E. ; Bianchi, L.

British journal of dermatology (1951), 2019-11, Vol.181 (5), p.1078-1079 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
3
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

Papp, K.A. ; Bachelez, H. ; Blauvelt, A. ; Winthrop, K.L. ; Romiti, R. ; Ohtsuki, M. ; Acharya, N. ; Braun, D.K. ; Mallbris, L. ; Zhao, F. ; Xu, W. ; Walls, C.D. ; Strober, B.

British journal of dermatology (1951), 2017-12, Vol.177 (6), p.1537-1551 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
4
A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
Material Type:
Artigo 		Adicionar ao Meu Espaço

A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study

Vries, A.C.Q. ; Thio, H.B. ; Kort, W.J.A. ; Opmeer, B.C. ; Stok, H.M. ; Jong, E.M.G.J. ; Horvath, B. ; Busschbach, J.J.V. ; Nijsten, T.E.C. ; Spuls, Ph.I.

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.624-633 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
5
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

Gisondi, P. ; Bianchi, L. ; Calzavara‐Pinton, P. ; Conti, A. ; Chiricozzi, A. ; Fimiani, M. ; Pellegrino, M. ; Giunta, A. ; Prignano, F. ; Tiberio, R. ; Venturini, M. ; Girolomoni, G.

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.409-410 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
6
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry

Zweegers, J. ; van den Reek, J.M.P.A. ; van de Kerkhof, P.C.M. ; Otero, M.E. ; Kuijpers, A.L.A. ; Koetsier, M.I.A. ; Arnold, W.P. ; Berends, M.A.M. ; Weppner-Parren, L. ; Ossenkoppele, P.M. ; Njoo, M.D. ; Mommers, J.M. ; van Lümig, P.P.M. ; Driessen, R.J.B. ; Kievit, W. ; de Jong, E.M.G.J.

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.340-347 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials
Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials

Nast, A. ; Dilleen, M. ; Liyanage, W. ; Aikman, L. ; Szczypa, P. ; Dressler, C.

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.400-405 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
8
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Iskandar, I.Y.K. ; Ashcroft, D.M. ; Warren, R.B. ; Evans, I. ; McElhone, K. ; Owen, C.M. ; Burden, A.D. ; Smith, C.H. ; Reynolds, N.J. ; Griffiths, C.E.M.

British journal of dermatology (1951), 2017-05, Vol.176 (5), p.1297-1307 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
9
Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis
Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis

Egeberg, A. ; Ottosen, M.B. ; Gniadecki, R. ; Broesby‐Olsen, S. ; Dam, T.N. ; Bryld, L.E. ; Rasmussen, M.K. ; Skov, L.

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.509-519 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
10
Comparison of the 1‐ and 5‐year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry
Comparison of the 1‐ and 5‐year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of the 1‐ and 5‐year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry

Zweegers, J. ; Groenewoud, J.M.M. ; Reek, J.M.P.A. ; Otero, M.E. ; Kerkhof, P.C.M. ; Driessen, R.J.B. ; Lümig, P.P.M. ; Njoo, M.D. ; Ossenkoppele, P.M. ; Mommers, J.M. ; Koetsier, M.I.A. ; Arnold, W.P. ; Andriessen, M.P.M. ; Kuijpers, A.L.A. ; Berends, M.A.M. ; Kievit, W. ; Jong, E.M.G.J.

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.1001-1009 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.